Drug Profile


Alternative Names: BCX-1777; Fodosine; Forodesine hydrochloride; Immucillin-H; Mundesine

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Albert Einstein College of Medicine; Industrial Research Limited
  • Developer BioCryst Pharmaceuticals; Mundipharma International
  • Class Antineoplastics; Antipsoriatics; Purine nucleosides; Pyrimidinones; Small molecules
  • Mechanism of Action Immunosuppressants; Purine nucleoside phosphorylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Hairy cell leukaemia; Cutaneous T cell lymphoma; Leukaemia; Acute lymphoblastic leukaemia; T cell prolymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase I Haematological malignancies
  • No development reported Chronic lymphocytic leukaemia; Cutaneous T cell lymphoma

Most Recent Events

  • 04 Apr 2017 Launched for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (PO)
  • 03 Apr 2017 Registered for Peripheral T-cell lymphoma (Second-line therapy or greater) in Japan (PO)
  • 27 Feb 2017 Preregistration for Peripheral T-cell lymphoma in Japan (PO) before February 2017 (BioCryst Pharmaceuticals 10-K, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top